(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 109.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.24%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.71%.
Bridgebio Pharma's revenue in 2025 is $127,415,000.On average, 6 Wall Street analysts forecast BBIO's revenue for 2025 to be $77,489,942,071, with the lowest BBIO revenue forecast at $35,697,575,360, and the highest BBIO revenue forecast at $116,529,797,864. On average, 6 Wall Street analysts forecast BBIO's revenue for 2026 to be $126,833,865,016, with the lowest BBIO revenue forecast at $94,408,693,984, and the highest BBIO revenue forecast at $171,595,206,664.
In 2027, BBIO is forecast to generate $232,010,694,631 in revenue, with the lowest revenue forecast at $169,924,256,328 and the highest revenue forecast at $289,226,312,704.